AptaBio Therapeutics Company Description

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs.

The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells.

Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH).

The company was founded in 2009 and is based in Yongin-Si, South Korea.

AptaBio Therapeutics Inc.

Country	South Korea
Founded	2009
Industry	Biological Products, Except Diagnostic Substances
CEO	Jin Soo

Contact Details

Address: Tower 504, 13 Yongin-si, 16954 South Korea
Phone	82 70 7152 0097
Website	aptabio.com

Stock Details

Ticker Symbol	293780
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Jin Soo	Chief Executive Officer